Source: Pixabay
TESARO and Takeda Pharmaceutical Company Limited have entered into an licensing agreement for the commercialisation and clinical development of novel cancer therapy niraparib.
Niraparib was first marketed in the U.S. in April under the brand name ZEJULA and has quickly become the most frequently prescribed PARP inhibitor in the U.S.
Under the agreement, TESARO will receive $100 million upfront payment and is eligible to receive additional milestone payments of up to $240 million related to the achievement of certain regulatory and commercial goals.
Christophe Bianchi, President of Takeda Oncology said, “The niraparib development program addresses many of the most prevalent and devastating cancers worldwide. We must continue to make new treatments available to patients and, through research, further our knowledge into the full utility of this molecule. We are pleased to be collaborating with TESARO, a company we admire for its high caliber oncology expertise. This agreement represents another step in our goal of building Takeda's robust portfolio in solid tumors and, more importantly, our commitment to patients living with cancer who desperately want - and need - new, innovative therapies."
Mary Lynne Hedley, Ph.D., President and COO of TESARO said, "TESARO is devoted to providing transformative therapies for people bravely facing cancer, and this partnership enables us to continue to globalize our mission. As the largest pharmaceutical company in Japan, Takeda is recognized as a leader in oncology, and we are excited to work with the Takeda team to quickly advance niraparib for patients who are in need of new treatment options."
